anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present disclosure provides inventive cosmetic/dermatological formulations and/or preparations that include mesenchymal stem cells (MSCs), and also provides associated methods for repairing, rejuvenating and/or augmenting skin tissue. The formulations and/or preparations include MSCs that are formulated into creams, lotions, and the like. In one aspect, the MSCs are obtained autogenously. In another aspect, the MSCs are obtained from allogeneic sources. In another aspect, the MSCs may be minimally manipulated. In another aspect, the MSCs may be derived from bone marrow or adipose tissue. In another aspect, the MSCs can be utilized from bone marrow concentrate (BMC) or from adipose stromal vascular fraction (SVF). In another aspect, the MSCs can also be utilized after cell expansion. The associated methods comprise topical application of the cosmetic/dermatological formulations and/or preparations onto skin tissue, resulting in repairing, rejuvenating, and/or augmenting the skin tissue.
Trigger finger causes pain and a persistent functional limitation of the hand, which can lead to permanent blockage of the flexor tendon. Ultrasonography-guided percutaneous release has been widely reported as a successful technique for trigger finger involving the A1 pulley. This article describes for the first time the use of this technique in an unusual location, the A3 pulley of the fifth finger. A 71-year-old patient presented with a 3-month history of pain and blockage in the fifth finger of the right hand and was diagnosed with a grade III trigger finger, according to the Froimson scale. We performed an ultrasonography-guided percutaneous release technique on the A3 pulley to release the flexor tendon of the fifth finger. Ultrasonography-guided percutaneous polectomy to treat trigger finger in the A1 pulley is an effective alternative treatment to surgery and even has certain advantages over it. The anatomical similarity between the A1 and A3 pulleys was the key factor that supported the use of this technique in this clinical case. Based on past experience in similar cases, we conclude that ultrasonography-guided percutaneous polectomy of the A3 pulley of the fifth finger was a surgical technique which could lead to a satisfactory outcome in the treatment of this condition.
The usual dietary potassium intake by the average adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause hypokalemia usually requires the loss of 200 mEq or more of potassium from the total body store.

Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of hypokalemia is typically in the range of 20 mEq per day. Doses of 40-100 mEq per day or more are used for the treatment of potassium depletion. Dosage should be divided if more than 20 mEq per day is given such that no more than 20 mEq is given in a single dose.

Each Klor-Con® Extended-release Tablet provides 8 mEq or 10 mEq of potassium chloride.

Klor-Con® Extended-release Tablets should be taken with meals and with a glass of water or other liquid. This product should not be taken on an empty stomach because of its potential for gastric irritation (see WARNINGS).

NOTE: Klor-Con® Extended-release Tablets must be swallowed whole and never crushed, chewed, or sucked.
1,178,622. Making capsules. CHAS. PFIZER & CO. Inc. 15 March, 1967 [23 Aug., 1966], No. 12260/67. Heading A5B. [Also in Divisions B5 and B8] Water-immiscible pharmaceutical materials are encapsulated by forming an aqueous dispersion thereof in a colloidal sol of a pharmaceutically acceptable hydrophilic polysaccharide or animal protein, centrifugally projecting minute portions of the dispersion completely through an unsupported film of warm, aqueous gelatin sol and cooling the resultant gelatin coated droplets. The apparatus described comprises a rotating head 10 on a vertical drive shaft 11 with a central feed device consisting of a tube 13 through which the gelatin sol is fed and a concentric inner tube 18 for the dispersion to be encapsulated. The gelatin sol passes under centrifugal force to the head containing an orifice 17 over which it forms a film and the dispersion passes to the nozzle 22 from which droplets are detached and pass through the gelatin film over the orifice 17. Thereafter, the coated droplets are cooled and collected. Specific reference is made to encapsulating fat-soluble vitamins, antibiotics, amphetamine, ephedrine, theophylline, hydroxyzine and oxyphencyclimine.
Nausea and vomiting are unpleasant events induced by multiple triggers. Among them, drugs frequently prompt nnaauusseeaa and vomiting. Antitumor chemotherapeutics are among the most emetic drugs and often cause the so- called chemotherapy-induced nausea and vomiting (CINV). The latter severely compromises the efficacy of therapy, as well as patient quality of life. There is a great interest in the identification of agents able to prevent and counteract drug- induced nausea and vomiting including CINV. Calcitonin gene related peptide (CORP) is a neuropeptide with pleiotypic effects in the human body. However, the neuropeptide effects in the brain still wait to be deciphered. Antibodies against CORP have been recently approved for migraine prevention. The use of anti- CGRP monoclonal antibodies for the direct treatment of nausea and vomiting including CINV is described.
Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy) phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Barium sulfate may also be provided to the core of the particles as a coating or absorbed within the core of the particles. The particles can be used to minimize blood flow to mammalian tissues by occluding at least a portion of a blood vessel of the mammal, or to deliver an active agent to a localized area within a body of a mammal by contacting a localized area with at least one of the particles. Further, the particles are useful in sustained release formulations including active agent(s) for oral administration, as tracer particles for injection into the bloodstream of a mammal or for use in enhanced ultrasound imaging. The particles may include agents for increasing density for achieving useful buoyancy levels in suspension.
Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.
Carer satisfaction with care leading up to the time of death and the quality of the patient's death. Questionnaire to be completed at baseline and every 8 weeks,and 5-7 weeks after patient deceased.
###  Oropharyngeal candidiasis

An open-label, comparative study of the efficacy and safety of DIFLUCAN (2 to 3 mg/kg/day) and oral nystatin (400,000 I.U. 4 times daily) was conducted in immunocompromised pediatric patients from 6 months to 13 years of age with oropharyngeal candidiasis. Clinical and mycological response rates were higher in pediatric patients treated with fluconazole. 

Clinical cure at the end of treatment was reported for 86% of fluconazole-treated patients compared to 46% of nystatin treated patients. Mycologically, 76% of fluconazole treated patients had the infecting organism eradicated compared to 11% for nystatin treated patients.

The proportion of patients with clinical relapse 2 weeks after the end of treatment was 14% for subjects receiving DIFLUCAN and 16% for subjects receiving nystatin. At 4 weeks after the end of treatment, the percentages of patients with clinical relapse were 22% for DIFLUCAN and 23% for nystatin.
Inflammation is an established pathway in the formation, growth, and rupture of atherosclerotic plaques. Inflammation is thus essential to the pathogenesis of coronary heart disease and some types of ischemic stroke.1 The benefit of anti-inflammatory therapies, such as colchicine2 and the anti-IL1β canakinumab,3 is proven in patients with coronary heart disease, yet it remains unproven for patients with ischemic stroke. Compared with coronary heart disease, the etiology of stroke is more heterogeneous. Besides arterio-arterial atherogenic embolism, possible etiologies are penetrator artery occlusion, cardioembolism, and other mechanisms. Finding a stroke etiology remains elusive in up to 30%-40% of patients despite a full evaluation. Understanding whether the stroke etiology modifies the association between inflammatory markers and recurrence risk is an important step to improve selection of patients for randomized trials on anti-inflammatory agents. IL-6 and high-sensitive CRP (hs-CRP) have been implicated in a higher recurrence risk after ischemic stroke by both an individual participant data meta-analysis4 and a Mendelian randomization study,5 but granular, in vivo results stratified by stroke etiology are lacking.
Renal fibrosis, inflammation, and gut dysbiosis are all linked to chronic kidney disease (CKD). Here we show that Bacteroides ovatus protects against renal fibrosis. Mechanistically, B. ovatus enhances intestinal hyodeoxycholic acid (HDCA) levels by upregulating a strain of intestinal bacteria, Clostridium scindens, that has the capacity for direct HDCA production in mice. HDCA significantly promoted GLP-1 secretion by upregulating the expression of TGR5 and downregulating the expression of farnesoid X receptor (FXR) in the gut. Activation of renal GLP-1R attenuates renal fibrosis while delaying the subsequent development of CKD. In addition, HDCA can also protect against renal fibrosis by directly upregulating renal TGR5. The natural product neohesperidin (NHP) was found to exert its anti-renal fibrotic effects by promoting the growth of B. ovatus. Our findings provide mechanistic insights into the therapeutic potential of B. ovatus, C. scindens, and HDCA in treating CKD.
PURPOSE:To obtain an external drug for skin effective in suppressing acne, dandruff, itchiness, etc., by using an extract of a plant belonging to Thujopsis genus, Thuja genus or Juniperus genus of Cupressaceae family, as an active component. CONSTITUTION:A plant belonging to Thujopsis genus (e.g. Thujopsis dolabrata, etc.), Thuja genus (e.g. Thuja standishii) or Juniperus genus (e.g. Juniperus rigida, Juniperus conferta, Juniperus chinensis, Juniperus chinensis var. procumbens, etc.) of Cupressaceae family is extracted with a solvent such as ethanol, propylene glycol, water, hexane, etc., and the extract (solution as extracted or concentrated extract produced by distilling out the solvent) is used as a component of the objective external agent for skin, e.g. drug, quasi- drug, cosmetic, etc. It is preferable to use the extract in an amount of 0.1-3wt% in terms of dried residue in the whole external agent, because the agent obtained thereby exhibits fungicidal activity against fungi causing acne, dandruff or itchiness.
Although a program of frequent laboratory monitoring for evidence of hepatocellular injury is deemed essential, it is not clear that periodic monitoring of liver enzymes will prevent the occurrence of fulminant liver failure. However, it is generally believed that early detection of drug-induced hepatic injury along with immediate withdrawal of the suspect drug enhances the likelihood for recovery. Accordingly, the following liver monitoring program is recommended.

Before starting treatment with Tolcapone tablets, the physician should conduct appropriate tests to exclude the presence of liver disease. In patients determined to be appropriate candidates for treatment with Tolcapone tablets, serum glutamic-pyruvic transaminase (SGPT/ALT) and serum glutamic-oxaloacetic transaminase (SGOT/AST) levels should be determined at baseline and periodically (i.e. every 2 to 4 weeks) for the first 6 months of therapy. After the first six months, periodic monitoring is recommended at intervals deemed clinically relevant. Although more frequent monitoring increases the chances of early detection, the precise schedule for monitoring is a matter of clinical judgment.

    If the dose is increased to 200 mg tid (see DOSAGE AND ADMINISTRATION), liver enzyme monitoring should take place before increasing the dose and then be conducted every 2 to 4 weeks for the following 6 months of therapy. After six months, periodic monitoring is recommended at intervals deemed clinically relevant.

Discontinue Tolcapone tablets if SGPT/ALT or SGOT/AST levels exceed 2 times the upper limit of normal or if clinical signs and symptoms suggest the onset of hepatic dysfunction (e.g., persistent nausea, fatigue, lethargy, anorexia, jaundice, dark urine, pruritus, and right upper quadrant tenderness).
The Quit Using Drugs Intervention Trial (QUIT) will be the first randomized controlled trial in the U.S. that is powered to detect the effect of a primary care clinician delivered brief intervention protocol for reducing 'at risk' drug use and drug-related harm among low-income adult patients (ages 18 and older) at multiple safety net clinics in Los Angeles County. For this small trial, we will sample patients with 'at risk' use of drugs (marijuana, crack/cocaine, amphetamines/methamphetamines, inhalants, sedatives or sleeping pills, hallucinogens, and opiates), the most commonly used serious drugs among patients at our clinic sites. "At risk" drug use is defined in this study as current use (past 90 days) of drug measured as a self-reported total score of 4 to 26 on the WHO Alcohol Substance Involvement Screening Test (ASSIST). A total of 7,000-8,000 patients will be approached for screening to yield a 3-month effective sample size of 245 eligible patients per condition (1) an intervention condition involving drug use health education or (2) a control condition involving care as usual. In the intervention condition, very brief (less than 5 minutes) clinician advice regarding quitting drug use will be followed by two 2 and 6 week post-visit drug health education sessions on quitting drug use and cautioning against use of other 'at risk' substance use such as alcohol and tobacco. Patients assigned to the control condition will receive standard care for drug use at the baseline visit with their clinician. Follow-up assessments will be conducted at 3 month post-randomization. The framework for the QUIT project is the Social Action Theory, and the brief intervention protocol is based on NIDA's principles on prevention research and the utility of the 5 A's approach for assisting behavioral changes among patients (Ask, Advise, Assess, Assist, Arrange) in the clinic setting. If found to be effective in the community health center setting, this clinician and telephone drug-use health education program could become a model for health promotion activities. that would be expanded to all 'at risk' substance use and shared between community health centers.
BACKGROUND: Standard precautions are the minimum standard of infection control to prevent transmission of infectious agents, protect healthcare workers, patients, and visitors regardless of infection status. The consistent implementation of standard precautions is highly effective in reducing transmission of pathogens that cause HAIs. Despite their effectiveness, compliance, resources, patient behavior, and time constraints are some of the challenges that can arise when implementing standard precautions. The main objective of this meta-analysis was to show the pooled prevalence of safe standard precaution practices among healthcare workers in Low and Middle Income Countries (LMICs).
METHODS: A systematic review and meta-analysis was conducted for this study. We systematically searched observational study articles from PubMed Central and Google Scholar. We included articles published any year and involving healthcare workers. We used Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). The random effect model was used to estimate the pooled prevalence. The meta-analysis, sensitivity analysis, subgroup analysis, and publication bias (funnel plot, and Egger's tests) were conducted.
RESULTS: A total of 46 articles were included in this study. The pooled prevalence of standard precautions practices among healthcare workers in LMICs was 53%, with a 95% CI of (47, 59). These studies had a total sample size of 14061 with a minimum sample size of 17 and a maximum sample size of 2086. The majority of the studies (82.6%) were conducted in hospitals only (all kinds), and the remaining 17.4% were conducted in all health facilities, including hospitals.
CONCLUSIONS: The pooled prevalence of standard precautions practices among healthcare workers in LMICs was suboptimal. The findings of this study can have substantial implication for healthcare practice and policy making by providing robust evidence with synthesized and pooled evidence from multiple studies.
TRIAL REGISTRATION: Registered on PROSPERO with record ID: CRD42023395129, on the 9th Feb. 2023.
Seventeen individuals received 1 liter/day of pasteurized orange juice. Participants consumed the orange juice before and post exercise, the volume of juice per serving was 500 mL. On players' rest days, the juice was consumed throughout the day.
The invention belongs to the field of ethnic minority medicines and discloses a Yao medicine composition for treating gout and a preparation method thereof. The composition comprises 2-20 parts by weight of fraxinus chinensis roxb., 4-40 parts by weight of zea mays L., 4-40 parts by weight of luffa cylindrica (L.) Roem., 4-40 parts by weight of plantago major L., 3-30 parts by weight of trachelosperumum jasminoides(Lindl.)Lam. and 2-20 parts by weight of clematis chinensis osbeck. The dosage form of the composition is powder or tea bags. The preparation method comprises the processes of grinding, baking and sterilizing the raw medicines, thus preparing the powder or tea bags. Clinical tests show that the medicine composition has the functions of clearing away heat and toxic materials, inducing diuresis for treating stranguria, dispelling the wind and eliminating dampness, dredging the channels and activating the collaterals, removing stasis to relieve pains and inducing diuresis to reduce edema, promotes uric acid metabolism and relieves joint pains, thus achieving the aims of health protection and treatment of gout; the Yao medicine composition takes effect quickly, has stable curative effects and no toxic or side effect and is a health protection medicine with preventive and therapeutic effects on gout.
FIELD: medicine, narcology. SUBSTANCE: method involves administration of specific immune preparations to patients for prophylaxis of infectious disease in alcoholic persons. In part case, for detection of HBsAg in pregnant: alcoholism prophylaxis in child is begun by the combined administration of hyperimmune gamma-globulin and vaccine based on HBs by the schedule: 1-st vaccination - immediately after delivery and then at age 1, 2, 3, 6, 12 months and the following booster vaccination at age 3-5 years (under control of anti-HBs in immunized child serum). Immunoglobulin HBIg is injected at dose 1 ml, intramuscularly, and hepatitis B subunit vaccine - at dose 3-40 mcg, subcutaneously. EFFECT: enhanced effectiveness of prophylaxis and treatment of alcoholism. 8 cl
Patients with right sided obstructive colon cancer will receive a right-sided stent. Prior to the definitive oncological resection, patients undergo preoperative optimisation which involves the engagement of a dietician and physiotherapist. Patients eligible for elective resection will be operated at least 7 days after initial decompression and no later than 4 weeks after initial presentation.
Patients should be advised that temporary blurring of vision, precipitation or worsening of narrow-angle glaucoma, mydriasis, increased intraocular pressure, acute eye pain or discomfort, visual halos or colored images in association with red eyes from conjunctival and corneal congestion may result if ipratropium bromide nasal solution, 0.06% comes into direct contact with the eyes. Patients should be instructed to avoid spraying ipratropium bromide nasal solution, 0.06% in or around their eyes. Patients who experience eye pain, blurred vision, excessive nasal dryness or episodes of nasal bleeding should be instructed to contact their doctor. To ensure proper dosing, patients should be advised not to alter the size of the nasal spray opening. Patients should be reminded to carefully read and follow the accompanying Patient's Instructions for Use.

Since dizziness, accommodation disorder, mydriasis, and blurred vision may occur with use of ipratropium bromide nasal solution, 0.06%, patients should be cautioned about engaging in activities requiring balance and visual acuity such as driving a car or operating appliances, machinery, etc.
Consecutive stage III melanoma patients 18 years or older referred to our institution for axillary or inguinal lymph node dissection is eligible for inclusion of the study. A bipolar vessel sealing device (LigaSure, Covidien) will be used for dissection in all procedures. All patients will be scheduled for an outpatient visit with an experienced nurse three weeks after the surgery. Any deviation from the normal postoperative course will be recorded in the electronic patient journal. Complications are graded according to the Clavien-Dindo classification. Patients with complications or with suspected complications at the three-week follow up will be scheduled for new an outpatient visit. Patient demographics, clinicopathological characteristics of the primary melanoma, indication for the procedure, length of postoperative stay and early complications and treatment for complications will be collected for analysis
PROBLEM TO BE SOLVED: To obtain a safe sustained release preparation capable of making a physiologically active peptide act in a living body for a long period of time stably and continuously, and having a high effectiveness by including the physiologically active peptide and a protein and a lipid derived from a living body. SOLUTION: This preparation in a state of a semi-solid kneaded with components A to C is obtained by incorporating (A) a physiologically active peptide, (B) a protein derived from a living body and (C) a lipid derived from a living body. The component A is preferably a peptide such as a cytokeine, growth factor, hormone, chemokeine, etc. The component B is preferably a protein such as albumin, a protein fraction of a plasma, a protein fraction of a serum, etc. Instead of or together with the component B, it is preferable to incorporate a derived from a living body. The component C is preferably a lipid such as a phospholipid, a fatty acid, a neutral fat, cholesterol and lipid soluble vitamin, etc. In the preparation, it is preferable to further add (D) an immunoadjuvant substance.